Latest Us Market Expansion News

Singular Health Group reported a $6.38 million loss for FY2025 while securing a pivotal $1.3 million commercial agreement with US-based Provider Network Solutions to deploy its 3DICOM software. The company also completed a major cloud migration of its platform, positioning itself for growth in the US healthcare market.

Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

Gladiator Resources has initiated the process to list on the US OTC Markets, aiming to enhance visibility and liquidity among North American investors as part of its rare earth elements growth strategy.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.

archTIS Limited has reported FY25 results with solid ARR growth and completed a transformative acquisition of Spirion LLC, significantly boosting its US market presence and product suite. The company is raising $20.5 million to fund this expansion and accelerate growth.

Zip Co Limited’s FY25 results reveal a powerful US market expansion driving a 147% rise in cash earnings and a strategic Nasdaq dual listing consideration.

Zip Co has delivered a standout FY25 with cash earnings soaring 147%, driven by rapid US market expansion. The company is now considering a Nasdaq dual listing to fuel further growth.

Zip Co Limited reported a robust FY25 with revenue up 23.5% to $1.07 billion and cash earnings soaring 147%, driven by strong US market expansion and operational efficiencies.

Atomo Diagnostics reports a significant expansion in its supply agreement with Lumos for the Pascal test cassette, tied to the promising CLIA waiver status of the FebriDx test in the US. This deal could nearly double Atomo’s revenues over the next three years.

QuickFee Limited posted a 25% increase in revenue to A$25.3 million for FY25, driven by strong growth in both Australia and the US, alongside a positive underlying EBTDA of A$2.4 million before a one-off credit loss provision.

Ovanti Limited has secured a strategic three-year partnership with Shift4 Payments to launch its innovative Buy Now Pay Later services across over 100,000 US merchants, leveraging AI-driven credit models and stablecoin-backed funding.